Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, Rutgers-Robert Wood Johnson University Hospital, Bristol Myers Squibb Children's Hospital.
Wood Johnson Medical School, New Brunswick, NJ.
J Pediatr Gastroenterol Nutr. 2020 Oct;71(4):e124-e128. doi: 10.1097/MPG.0000000000002853.
Recently, significant interest from families and healthcare providers has arisen to use blenderized tube feedings (BTF). Although many institutions are providing this nutritional option, literature documenting outcomes and safety is lacking.
A retrospective chart review was performed on pediatric patients receiving BTF at Rutgers-Robert Wood Johnson University Hospital between January 2013 and April 2017. Demographic data and dietary information before and after BTF were collected. Reasons for diet initiation, symptoms, and anthropometrics were recorded. Adverse events and outcomes were assessed through physician documentation and relevant medication changes.
Thirty-five patients (24 boys) received BTF. Age at initiation of BTF ranged from 1 to 19 years (mean 8.3 +/- 5.8 [SD] years). Length of follow-up ranged from 1 to 45 months (mean 15 +/- 12.2 months). The most common reason for starting BTF was gastroesophageal reflux disease (GERD) (N = 32). Almost all patients were on medications for GERD, constipation, or gastrointestinal dysmotility before starting BTF (N = 33). Majority of patients had improvement in relevant symptoms (N = 20); 13 of 33 patients on gastrointestinal medications were able to wean or stop medication(s). BMI z scores did not differ before and after BTF initiation (P = 0.558). No serious life-threatening adverse events were found.
Our data suggest that BTF is a safe dietary intervention that may improve gastrointestinal symptoms in pediatric patients. Further prospective studies are needed to compare safety and efficacy of BTF and commercial formulas in pediatric patients.
最近，患者家庭和医疗保健提供者对使用搅拌管饲（BTF）产生了浓厚的兴趣。尽管许多机构都提供了这种营养选择，但缺乏记录结果和安全性的文献。
对 2013 年 1 月至 2017 年 4 月期间在罗格斯-罗伯特伍德·约翰逊大学医院接受 BTF 的儿科患者进行了回顾性图表审查。收集了 BTF 前后的人口统计学数据和饮食信息。记录了开始饮食的原因、症状和人体测量学数据。通过医生的记录和相关药物变化评估不良事件和结果。
35 名患者（24 名男性）接受了 BTF。BTF 开始时的年龄从 1 岁到 19 岁（平均 8.3±5.8[SD]岁）。随访时间从 1 到 45 个月不等（平均 15±12.2 个月）。开始 BTF 的最常见原因是胃食管反流病（GERD）（N=32）。几乎所有患者在开始 BTF 之前都服用 GERD、便秘或胃肠道动力障碍的药物（N=33）。大多数患者相关症状都有所改善（N=20）；33 名胃肠道药物治疗的患者中有 13 人能够减少或停止用药。BTF 开始前后 BMI z 评分无差异（P=0.558）。未发现严重危及生命的不良事件。
我们的数据表明，BTF 是一种安全的饮食干预措施，可改善儿科患者的胃肠道症状。需要进一步的前瞻性研究来比较 BTF 和商业配方在儿科患者中的安全性和疗效。
Zotero 插件